Literature DB >> 7049355

Heterogeneity of HLA-A,B, Ia-like, and melanoma-associated antigen expression by human melanoma cell lines analyzed with monoclonal antibodies and flow cytometry.

S W Burchiel, J C Martin, K Imai, S Ferrone, N L Warner.   

Abstract

With the use of monoclonal antibodies, indirect immunofluorescence, and flow cytometry, human melanoma cell lines (Colo 38, M-16, and M-21) were examined for the quantitative level of expression of HLA-A,B antigens, Ia-like antigens, and two human melanoma-associated antigens (MAA) referred to as 280K and 94K MAAs. Each of the melanoma cell lines examined showed tremendous heterogeneity with regard to antigen expression. A detailed study of the heterogeneity of the four antigens listed revealed that variation in cell size could, in part, account for the large differences in antigen expression observed. Cell surface density of HLA-A,B antigens, Ia-like antigens, and the 280K and 94K MAAs remained relatively constant over a wide range of cell sizes that were examined, with the exception that small melanoma cells showed a slightly lower mean surface density of MAA expression than did large cells. A novel method was used to detect the expression of the two MAAs as a function of the Colo 38 cell cycle using dual-laser beam flow cytometry. The results of these experiments show that both the 280K MAA and the 94K MAA are differentially expressed during various stages of the cell cycle, with each antigen being maximally detected during G2 + M.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7049355

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Heterogeneous expression of a murine B16 melanoma-associated antigen correlates with cell cycle.

Authors:  S P Leong; P D Noguchi; R E Cunningham; T Takami; J A Roth
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  DNA mismatch repair enzyme hMSH2 in malignant melanoma: increased immunoreactivity as compared to acquired melanocytic nevi and strong mRNA expression in melanoma cell lines.

Authors:  K Rass; P Gutwein; C Welter; V Meineke; W Tilgen; J Reichrath
Journal:  Histochem J       Date:  2001-08

3.  Immunohistological analysis of the lymphoid infiltrate in cutaneous malignant melanomas.

Authors:  E Ralfkiaer; K Hou-Jensen; K C Gatter; K T Drzewiecki; D Y Mason
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

4.  Quantitative variation of the common acute lymphoblastic leukemia antigen (gp100) on leukemic marrow blasts.

Authors:  A T Look; S L Melvin; L K Brown; M E Dockter; P K Roberson; S B Murphy
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

5.  Selective in vitro toxicity of purothionin conjugated to the monoclonal antibody 225.28S to a human high-molecular-weight melanoma-associated antigen.

Authors:  K Imai; T Nakanishi; T Noguchi; A Yachi; S Ferrone
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

6.  Functional consequence of variation in melanoma antigen expression.

Authors:  L M Zehngebot; M A Alexander; D Guerry; D B Cines; K Mitchell; M Herlyn
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

7.  Biological characterization of human bone tumors. VIII. Expression of HLA-DR antigens in bone tumors and tumor-like lesions.

Authors:  M Petzsch; J Vassallo; A Roessner; G Zwadlo; C Sorg; E Vollmer; E Grundmann
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

Review 8.  Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells.

Authors:  G Parmiani; G Fossati; D Taramelli; A Anichini; A Balsari; C Gambacorti-Passerini; G Sciorelli; N Cascinelli
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

Review 9.  Radioimmunotherapy of malignancy using antibody targeted radionuclides.

Authors:  L M Cobb; J L Humm
Journal:  Br J Cancer       Date:  1986-12       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.